Encouraging results for long-term efficacy of meningitis C vaccine


NB. Please note that if you are outside North America, the embargo for LANCET press material is 0001 hours UK Time 23 July 2004.

Four-year results assessing the efficacy of the UK meningitis C vaccine programme are reported in a research letter in this week's issue of THE LANCET. The vaccine is now showing long-term efficacy, except for infants initially vaccinated younger than 5 months of age.

The meningococcal serogroup C conjugate (MCC) vaccine programme was introduced in November 1999 and has successfully controlled the incidence of meningitis C--a result of high short-term vaccine effectiveness and substantial herd (population) immunity. However, the long-term effectiveness of the vaccine remains unknown.

Caroline Trotter (UK Health Protection Agency) and colleagues assessed surveillance data from the 4 years since the introduction of the vaccination programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years) at around 90%. However, overall vaccine effectiveness was only 66% for children vaccinated in early infancy. the vaccine offered high levels of protection (>93% effectiveness) for one year, regardless of the age of the child at vaccination; however this protection rapidly diminished for children who were vaccinated in early infancy (younger than 5 months of age). With regard to this reduced protection, the authors comment: 'The number of cases of serogroup C disease in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.'

Paul A Offit (University of Pennsylvania School of Medicine, Philadelphia, USA) gives an overall perspective on the UK MCC vaccination programme in an accompanying commentary (p 309): "The UK Department of Health showed how to efficiently implement an effective mass-immunisation programme with a conjugate meningococcal vaccine. The Department characterised the burden of serogroup C meningococcal infections, identified a vaccine to solve the problem, actively engaged several drug companies in the programme, and negotiated an affordable price, launched a media campaign to educate citizens about the disease and the vaccine, and immunised a remarkably high percentage of children within a year. For their efforts, the Department of Health deserves the gratitude of children and their parents throughout the world".

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.



Men will always be mad, and those that think they can cure them are the maddest of them all.
-- Voltaire